ANL Stock Forecast & Price Target

Adlai Nortye is attractive because its lead program AN9025 builds on clinically validated pan-RAS(ON) biology while showing unusually strong preclinical potency, including 100x greater cellular potency and comparable or superior in vivo efficacy at 1/250th the dose of daraxonrasib, which supports a potentially wider therapeutic window and combination flexibility. The company also has meaningful pipeline diversification through AN4035, a CEACAM5-targeted pan-RAS(ON) ADC, plus AN8025 and AN4005 in next-generation immunotherapy, while the FDA’s Study-May-Proceed letter on AN4035 improves regulatory visibility and the ASK Pharma deal provides more than $20 million upfront/near-term milestones, up to about $230 million total, and ex-China global optionality. Valuation remains asymmetric, with a market cap of roughly $730 million versus larger RAS peers, and a positive Phase 1 readout in 1H27 could materially de-risk the story and drive re-rating.

Adlai Nortye is fundamentally challenged by a precommercial profile with no revenue from product sales, ongoing operating losses, and a need for additional funding that raises the risk of dilutive capital raises before any asset can generate meaningful cash flow. Its lead programs remain highly speculative because AN9025 still lacks clinical validation and faces a difficult systemic pan-RAS therapeutic window, where on-target, off-tumor toxicity could constrain dosing, combinations, and durability despite promising preclinical data. Even with AN4035 progressing toward an IND filing this summer and business development transactions offering some validation, the company faces heavy execution risk from failed or inconclusive trials and larger, better-resourced competitors that could out-innovate or outspend it.